以岭药业：达格列净化学原料药上市申请已获批准

Core Viewpoint - Yiling Pharmaceutical's wholly-owned subsidiary, Hengshui Wanyang, has received approval for the market launch of Dapagliflozin, a selective SGLT-2 inhibitor for treating type 2 diabetes [1] Company Summary - Dapagliflozin is designed to block glucose reabsorption in the kidneys, promoting glucose excretion and lowering blood sugar levels [1] - The approval of Dapagliflozin is expected to enhance Yiling Pharmaceutical's product portfolio in the diabetes treatment market [1] Industry Summary - The Chinese diabetes medication market is projected to reach 52.7 billion yuan in 2024, with Dapagliflozin expected to capture a market share of 12.83% [1] - The market capacity for Dapagliflozin in China is anticipated to grow to 7.38 billion yuan in 2025, representing a year-on-year increase of 35% [1] - Sales volume for Dapagliflozin is expected to reach 1.78 billion tablets in 2025, reflecting a growth of 38% year-on-year [1] - The demand for Dapagliflozin raw materials in China is projected to be 17.48 tons in 2024, showing a year-on-year increase of 38.51% [1]